This expanded partnership creates a significant operational and regulatory compliance burden, requiring robust systems to manage equally shared development costs, profit splits, and distinct regulatory leadership for US (Regeneron) and ex-US (Sanofi) markets.
Filing excerpt
On October 1, 2026, Regeneron Pharmaceuticals, Inc.... Sanofi Biotechnology SAS... and Sanofi... entered into the Sixth Amendment to the Amended and Restated License and Collaboration Agreement
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Regions named
sec-8kcomplianceBurdenGet every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/af501570-2787-4933-90d1-e9586e9da39f returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "af501570-2787-4933-90d1-e9586e9da39f",
"signal_type": "sec-8k",
"signal_subtype": "complianceBurden",
"detected_at": "2026-10-13T07:04:59.03+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "This expanded partnership creates a significant operational and regulatory compliance burden, requiring robust systems to manage equally shared development costs, profit splits, and distinct regulatory leadership for US (Regeneron) and ex-US (Sanofi) markets.",
"metrics": {
"timeframe": "immediate",
"dollar_context": "Upfront payment from Sanofi to Regeneron, providing capital for shared development costs. Regeneron is also eligible for up to $7.0 billion in milestone payments.",
"dollar_millions": 1000
},
"summary": "Regeneron & Sanofi expand collaboration to co-develop 4 new antibodies with shared global costs.",
"excerpts": "On October 1, 2026, Regeneron Pharmaceuticals, Inc.... Sanofi Biotechnology SAS... and Sanofi... entered into the Sixth Amendment to the Amended and Restated License and Collaboration Agreement",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm",
"filing_date": "2026-10-06",
"filing_year": 2026,
"sales_relevance": "GRC tools needed",
"signal_category": "risk",
"regions_mentioned": [
"United States"
],
"technologies_mentioned": [
"antibodies",
"bispecific antibody",
"Nanobody® VHH therapy"
]
}
}
curl https://signals.autobound.ai/v1/signals/af501570-2787-4933-90d1-e9586e9da39f \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.